A Randomized Controlled Trial of Ultrasonic Aspiration versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia

Primary Objective

The primary objective of this study is to evaluate the incidence of vulva dysplasia recurrence within 12 months of treatment with CO2 laser ablation or ultrasonic aspiration. Women referred for treatment following diagnosis of VIN II/III will be randomized to receive CO2 laser ablation (typical treatment for these cases) or ultrasonic aspiration (approved treatment providing a more targeted technique). Secondary objectives will examine incidences of pain, scarring, and sexual and psychosocial distraught following treatment for high-grade dysplasia.

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

Inclusion criteria: ? Women 18-89 years old ? Diagnosed with VIN II/III (diagnosed by pathology) ? Referred for vulva sparing treatment for dysplasia ? Available for follow-up of treatment for 12 months Exclusion criteria: ? Women who are pregnant ? Women with VIN I dysplasia (diagnosed by pathology) ? Women with vaginal intraepithelial neoplasia (VAIN) ? Women requiring vulvectomy for treatment ? Women unable to provide informed consent

Type of Study

Treatment

Locations

Denver Health and Hospital Authority
Regional West Medical Center
University of Colorado Hospital
University of Oklahoma

Study ID

Protocol Number: 16-0701

More information available at ClinicalTrials.gov: NCT02875561

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers